Wang Chen, Diao Hongcui, Ren Ping, Wang Xufu, Wang Yangang, Zhao Wenjuan
Department of Endocrine and Metabolic Diseases, the Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Endocrine, Yiyuan County People's Hospital, Zibo, China.
Front Oncol. 2018 Dec 20;8:640. doi: 10.3389/fonc.2018.00640. eCollection 2018.
Radioiodine (I) thyroid remnant ablation is an important treatment of differentiated thyroid carcinoma (DTC) and various factors affecting its efficacy have been reported but not well defined. The aim of our study was to evaluate the efficacy and the affecting factors of I ablation after total or near-total thyroidectomy in a relative large DTC cohort. 261 DTC patients with negative thyroglobulin antibody received 100-200 mCi I for thyroid remnant ablation after total or near-total thyroidectomy between January 2012 and October 2015 in our hospital. The efficacy and affecting factors of I ablation therapy were retrospectively investigated. The success rate of the first I thyroid remnant ablation was 65.90%. Univariate analysis demonstrated that larger tumor size, higher level of pre-ablation stimulated thyroglobulin (sTg), intermediate to high risk stratification for recurrence, and lymph node and distant metastases were associated with a lower success rate of the first I ablation (all < 0.05). Multivariate logistic regression analysis showed that tumor size, pre-ablation sTg, and lymph node and distant metastases were independent factors affecting the efficacy of the first I ablation. Areas under receiver operating characteristic curves for sTg, sTg/TSH ratio, and tumor size to predict unsuccessful ablation were 0.831, 0.824, and 0.648, respectively. The threshold values were 4.595 ng/ml, 0.046 mg/IU, and 1.350 cm, respectively. The sensitivities were 95.51, 96.63, and 73.03% and the specificities were 64.54, 61.63, and 49.41%, respectively. The excellent response (ER) ratio of the successful group was significantly higher than that of the unsuccessful group. The efficacy of the first I thyroid remnant ablation after surgical treatment of DTC is well demonstrated, and tumor size, pre-ablation sTg, lymph node, and distant metastases are independent factors affecting its efficacy.
放射性碘(I)甲状腺残余组织消融是分化型甲状腺癌(DTC)的重要治疗方法,已有多种影响其疗效的因素被报道,但尚未明确界定。我们研究的目的是在一个相对较大的DTC队列中评估全甲状腺切除或近全甲状腺切除术后I消融的疗效及影响因素。2012年1月至2015年10月期间,我院261例甲状腺球蛋白抗体阴性的DTC患者在全甲状腺切除或近全甲状腺切除术后接受了100 - 200 mCi的I进行甲状腺残余组织消融。对I消融治疗的疗效及影响因素进行回顾性研究。首次I甲状腺残余组织消融的成功率为65.90%。单因素分析表明,肿瘤体积较大、消融前刺激甲状腺球蛋白(sTg)水平较高、复发风险分层为中高危、伴有淋巴结及远处转移与首次I消融成功率较低相关(均P<0.05)。多因素logistic回归分析显示,肿瘤体积、消融前sTg以及淋巴结和远处转移是影响首次I消融疗效的独立因素。用于预测消融失败的sTg、sTg/TSH比值和肿瘤体积的受试者操作特征曲线下面积分别为0.831、0.824和0.648。阈值分别为4.595 ng/ml、0.046 mg/IU和1.350 cm。敏感性分别为95.51%、96.63%和73.03%,特异性分别为64.54%、61.63%和49.41%。成功组的良好反应(ER)率显著高于失败组。DTC手术治疗后首次I甲状腺残余组织消融的疗效得到了充分证明,肿瘤体积、消融前sTg、淋巴结及远处转移是影响其疗效的独立因素。